Skip to main content
NCBI home page
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
. 2007 May 1;8(1):109–116. doi: 10.1111/j.1582-4934.2004.tb00265.x

Topical superoxide dismutase reduces post‐irradiation breast cancer fibrosis

F Campana 1, S Zervoudis 1,2,3,✉, B Perdereau 1, E Gez 1, A Fourquet 1, C Badiu 3, G Tsakiris 2, S Koulaloglou 2
PMCID: PMC6740277  PMID: 15090266

Abstract

Fibrosis following breast radiotherapy for mammary cancer is a frequent undesired effect with objective (esthetic) and subjective (pain) consequences. Forty‐four patients with clinical radiofibrosis following conservative treatment of breast cancer were evaluated for the local antifibrosis effect of copper zinc superoxide dismutase [SOD(Cu/Zn)]. Extracted SOD(Cu/Zn) in a concentration of 3,600 units/mg was applied as ointment to the fibrotic affected area, b.i.d. for 90 days, in a total dose of 40 mg. The radiofibrosis intensity was scored on the basis of clinical criteria (pain and the fibrosis area) before and after SOD(Cu/Zn) treatment. SOD(Cu/Zn) was found to be effective in reducing radiation induced fibrosis by a lowering pain score in 36/39 patients and a decrease of the fibrotic area size in half cases, after 6 months. The intensity and changes of breast fibrosis were assessed also by mammography and, for the topographical distribution of subcutaneous temperature, by infrared thermography. Mammography density suggested decreased fibrosis in one third of patients. Thermography showed that fibrosis was accompanied by two zones clinically indistinctive: a central area with maximum thermal activity, called “Maximal Thermic zone” (MTZ) and a peripheral area with less thermal activity but higher than in the surrounding normal tissue, “Transitional Thermic Zone” (TTZ). Both MTZ and TTZ were significantly decreased in 36/44 patients after SOD(Cu/Zn) treatment. Clinical changes persisted all along the study. Treatment was well tolerated except for one case of local allergic reaction, and no important side effects. Molecular mechanisms involved are discussed. Further studies are running to confirm and explain these results.

Keywords: breast irradiation, free radicals, SOD (Cu/Zn), superoxyde dismutase, radiofibrosis

References

  • 1. Calle R., Pilleron J.P., Schlienger P., Vilcoq J.R., Conservative management of operable breast cancer: ten years experience at the Foundation Curie, Cancer, 42: 2045–2053, 1978. [DOI] [PubMed] [Google Scholar]
  • 2. Habibollahi F., Mayles H.M., Mayles W.P., Winter P.J., Tong D., Fentiman I.S., Chaudary M.A., Hayward J.L., Assessment of skin dose and its relation to cosmesis in the conservative treatment of early breast cancer, Int. J. Radiat. Oncol. Biol. Phys., 14: 291–296, 1988. [DOI] [PubMed] [Google Scholar]
  • 3. Levit S.H., Perez C.A., Breast cancer In: Principles and Practice of Radiation Oncology, edited by Perez CA. and Brady LW. J.B. Lippincott, 1987, p. 730–792. [Google Scholar]
  • 4. Borger J.H., Kemperman H., Smitt H.S., Hart A., Van Dongen J., Lebesque J., Bartelink H., Dose and volume effects on fibrosis after breast conservation therapy, Int. J. Radiat. Oncol. Biol. Phys., 30: 1073–1081, 1994. [DOI] [PubMed] [Google Scholar]
  • 5. Turesson I., Notter G., The influence of fraction size in radiotherapy on the late normal tissue reaction—I: Comparison of the effects of daily and once‐a‐week fractionation on human skin, Int. J. Radiat. Oncol. Biol. Phys., 10: 593–598, 1984. [DOI] [PubMed] [Google Scholar]
  • 6. Van Limbergen E., Rijnders A., van der S.E. , Lerut T., Christiaens R., Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results, Radiother: Oncol., 16: 253–267, 1989. [DOI] [PubMed] [Google Scholar]
  • 7. Fleck R., McNeese M.D., Ellerbroek N.A., Hunter T.A., Holmes F.A., Consequences of breast irradiation in patients with pre‐existing collagen vascular diseases. Int. J. Radiat. Oncol. Biol. Phys., 17: 829–833, 1989. [DOI] [PubMed] [Google Scholar]
  • 8. Wazer D.E., DiPetrillo T., Schmidt‐Ullrich R., Weld L., Smith T.J., Marchant D.J., Robert N.J., Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early‐stage breast carcinoma, J. Clin. Oncol., 10: 356–363, 1992. [DOI] [PubMed] [Google Scholar]
  • 9. Beadle G.F., Come S., Henderson I.C., Silver B., Hellman S., Harris J.R., The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 10: 2131–2137, 1984. [DOI] [PubMed] [Google Scholar]
  • 10. Turesson I., Individual variation and dose dependency in the progression rate of skin telangiestasia. Int. J. Radiat. Oncol. Biol. Phys., 19: 1569–1574, 1990. [DOI] [PubMed] [Google Scholar]
  • 11. Del Maestro R., Thaw H.H., Bjork J., Planker M., Arfors K.E., Free radicals as mediators of tissue injury, Acta Physiol. Scand. Suppl., 492: 43–57, 1980. [PubMed] [Google Scholar]
  • 12. Michelson A.M., Toxicity of superoxide radical anions In: Superoxide and Superoxide Dismutase, edited by Michelson AM, McCord I.M. and Fridovich Academic Press, 1977, p. 245–256. [Google Scholar]
  • 13. Niwa Y., Oxidative injury and its defense system in vivo , Rinsho Byori, 47: 189–209, 1999. [PubMed] [Google Scholar]
  • 14. Klug D., Rabani J., Fridovich I., A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis, J. Biol. Chem., 247: 4839–4842, 1972. [PubMed] [Google Scholar]
  • 15. Tainer J.A., Getzoff E.D., Richardson J.S., Richardson D.C., Structure and mechanism of copper, zinc superoxide dismutase, Nature, 306: 284–287, 1983. [DOI] [PubMed] [Google Scholar]
  • 16. Monte M., Sacerdote D.L., Free radicals of oxygen and superoxide dismutase. Biological and medical aspects, Medicina (B. Aires), 54: 61–68, 1994. [PubMed] [Google Scholar]
  • 17. Petkau A., Scientific basis for the clinical use of superoxide dismutase. Cancer Treat.Rev., 13: 17–44, 1986. [DOI] [PubMed] [Google Scholar]
  • 18. Lorette G., Machet L., Radiation‐induced skin toxicities: prevention, treatment, Cancer Radiother., 5 Suppl 1: 116s–120s, 2001. [PubMed] [Google Scholar]
  • 19. Jones J.B., Cramer H.M., Inch W.R., Lampe H.B., Radioprotective effect of free radical scavenging enzymes. J. Otolaryngol., 19: 299–306, 1990. [PubMed] [Google Scholar]
  • 20. Overgaard J., Nielsen O.S., Overgaard M., Steenholdt S., Jakobsen A., Sell A., Lack of radiation protective effect of orgotein in normal and malignant mammalian cells. Acta Radiol. Oncol. Radiat. Phys. Biol., 18: 305–312, 1979. [DOI] [PubMed] [Google Scholar]
  • 21. Petkau A., Chelack W.S., Radioprotection by superoxide dismutase of macrophage progenitor cells from mouse bone marrow. Biochem. Biophys. Res. Commun., 119: 1089–1095, 1984. [DOI] [PubMed] [Google Scholar]
  • 22. Frick J., Danner C., Kunit G., Clinical experiences with orgotein in urologic diseases, Eur. J. Rheumatol. Inflamm., 4: 260–263, 1981. [PubMed] [Google Scholar]
  • 23. Housset M., Baillet F., Michelson A.M., Puget K. Action of liposomal superoxide dismutase on measurable radiation‐induced fibrosis, Ann. Med. Interne (Paris), 140: 365–367, 1989. [PubMed] [Google Scholar]
  • 24. Delanian S., Baillet F., Huart J., Lefaix J.L., Maulard C., Housset M. Successful treatment of radiation‐induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial, Radiother. Oncol., 32: 12–20, 1994. [DOI] [PubMed] [Google Scholar]
  • 25. Benyahia B., Campana F., Perdereau B., Gez A., Fourquet A., Magdelenat H. The effects of superoxide dismutase topical treatment on human skin radiofibrosis: a pathological study, The Breast, 5: 75–81, 1996. [Google Scholar]
  • 26. Seth L.R., Kharb S., Kharb D.P., Serum biochemical markers in carcinoma breast. Indian J. Med. Sci., 57: 350–354, 2003. [PubMed] [Google Scholar]
  • 27. Ray G., Batra S., Shukla N.K., Deo S., Raina V., Ashok S., Husain S.A., Lipid peroxidation, free radical production and antioxidant status in breast cancer, Breast Cancer Res. Treat., 59: 163–170, 2000. [DOI] [PubMed] [Google Scholar]
  • 28. Knight J.A., Onay U.V., Wells S., Li H., Shi E.J., Andrulis I.L., Ozcelik H., Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry, Cancer Epidemiol. Biomarkers Prev., 13: 146–149, 2004. [DOI] [PubMed] [Google Scholar]
  • 29. Duan H., Zhang H.J., Yang J.Q., Oberley L.W., Futscher B.W., Domann F.E., MnSOD up‐regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells, Antioxid. Redox. Signal., 5: 677–688, 2003. [DOI] [PubMed] [Google Scholar]
  • 30. Huber W., Orgotein—(bovine Cu‐Zn superoxide dismutase), an anti‐inflammatory protein drug: discovery, toxicology and pharmacology. Eur. J. Rheumatol. Inflamm., 4: 173–182, 1981. [PubMed] [Google Scholar]
  • 31. Carson S., Vogin E.E., Huber W., Schulte T.L., Safety tests of orgotein, an antiinflammatory protein, Toxicol. Appl. Pharmacol., 26: 184–202, 1973. [DOI] [PubMed] [Google Scholar]
  • 32. Nielsen O.S., Overgaard J., Overgaard M., Steenholdt S., Jakobsen A., Sell A., Orgotein in radiation treatment of bladder cancer. A report on allergic reactions and lack of radioprotective effect, Acta Oncol., 26: 101–104, 1987. [DOI] [PubMed] [Google Scholar]
  • 33. Delanian S., Martin M., Bravard A., Luccioni C., Lefaix J.L., Abnormal phenotype of cultured fibroblasts in human skin with chronic radiotherapy damage. Radiother. Oncol., 47: 255–261, 1998. [DOI] [PubMed] [Google Scholar]
  • 34. Somack R., Saifer M.G., Williams L.D., Preparation of long‐acting superoxide dismutase using high molecular weight polyethylene glycol (41,000–72,000 daltons), Free Radic. Res. Commun., 12–13 Pt 2: 553–562, 1991. [DOI] [PubMed] [Google Scholar]
  • 35. Mehvar R., Modulation of the Pharmacokinetics and Pharmacodynamics of Proteins by Polyethylene Glycol Conjugation, J. Pharm. Pharmaceut. Sci., 3: 125–136, 2000. [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES